drugset / Trial / NCT00720798
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
NaSingle-groupOpen-labelTreatment
Summary
This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 \[Roche protocol WA18062\], NCT00106574 \[Roche protocol WA18063\], and NCT00109408 \[Roche protocol WA17824\]) of adults with rheumatoid arthritis. Participants received tocilizumab alone or in combination with standard anti-rheumatic treatment.
Timeline
- Start
- 2005-09
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Background | Azathioprine | Small molecule | — | — |
| Background | Chloroquine | Small molecule | — | — |
| Background | Hydroxychloroquine | Small molecule | — | — |
| Background | Leflunomide | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Sulfasalazine | Small molecule | — | — |